Arich Enterprise Co Ltd

Arich Enterprise Co Ltd maintains a strong liquidity position, with a current ratio of 1.38, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt metric suggests a stable cash flow environment, supported by an operating cash flow of TWD 477.8 million and a free cash flow of TWD 25.2 million. However, the company's net cash position is negative after subtracting total debt, which may signal potential liquidity risk.

In terms of profitability, Arich Enterprise Co Ltd reports a return on equity (ROE) of 1.12% and a return on assets (ROA) of 0.38%, both of which are below the industry median for pharmaceutical companies. This suggests the company is underperforming in terms of capital efficiency and asset utilization. The operating margin is 7.3%, which is in line with the industry average, but the net margin of 0.7% is significantly lower, indicating higher-than-average operating expenses or tax burdens.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory risks. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or markets.

Looking ahead, the company's revenue is projected to grow by 2.5% in the current fiscal year and 1.8% in the next fiscal year, based on the outlook data. This modest growth is in line with the broader industry trend but does not suggest a strong competitive position. The company's capital expenditure is minimal, with a negative value of TWD 605,000, indicating a focus on cost control rather than expansion.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.01, indicating a conservative capital structure with limited leverage. However, the negative net cash position after debt is a red flag for liquidity risk. The dilution risk is low, with no significant dilution sources identified in the risk assessment.

Recent filings and transcripts do not indicate any major strategic shifts or operational disruptions. The company appears to be maintaining a stable but low-growth trajectory, with no significant R&D or capex initiatives disclosed.

Revenue grew 19.2% year-over-year to TWD 1.55 billion, demonstrating strong top-line expansion momentum.

Operating margin of 7.3% significantly exceeds the pharmaceutical cohort median of 5.45%, indicating superior profitability.

Net margin of 6.86% is well above the industry median of 3.86%, reflecting efficient cost management.

Cash conversion ratio of 22.34 is best-in-class compared to the cohort median of 0.95.

Debt-to-equity ratio of 0.01 is substantially lower than the cohort median of 0.18, ensuring financial stability.

Free cash flow decreased 4.3% year-over-year to TWD 58.2 million, reducing liquidity generation.

Long-term debt surged to TWD 631.6 million in FY0, raising leverage concerns despite low D/E.

Medium liquidity risk flags potential challenges in meeting short-term obligations or trading constraints.